Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 10, 2020
What happens to cancer survivors attending a structured cancer survivorship clinic? Symptoms, quality of life and lifestyle changes over the first year at the Sydney Cancer Survivorship Centre clinicJ L Vardy, A Liew, J Turner, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Acta Virologica|October 6, 2015
Preparation and identification of an antiserum against recombinant UL31 protein of pseudorabies virusM S Cai, S Jiang, C C Mo, et al.
JMIR Research Protocols|December 19, 2024
Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled TrialAmber J Normann, Clifton C Mo, Rebekah L Wilson, et al.
Expert Review of Hematology|July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomideYuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery|January 17, 2023
[The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy]Q C Yang, H K Zhou, C Yue, et al.
Expert Opinion on Biological Therapy|March 17, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)Yuxin Liu, Ji Hyun Lee, Clifton C Mo, et al.
Blood Reviews|June 9, 2024
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotideClifton C Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Advances|February 9, 2021
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experienceKatie Maurer, Anna Saucier, Haesook T Kim, et al.
Pageof 11